Douglas Lane & Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$71M Sell
552,155
-9,737
-2% -$1.14M 0.96% 33
2026
Q1
$67.6M Sell
561,892
-3,937
-0.7% -$455K 0.97% 34
2025
Q4
$59.6M Buy
565,829
+26,479
+5% +$2.49M 0.82% 45
2025
Q3
$45.3M Buy
539,350
+19,449
+4% +$1.6M 0.63% 67
2025
Q2
$41.2M Buy
519,901
+8,486
+2% +$675K 0.6% 65
2025
Q1
$45.9M Sell
511,415
-8,174
-2% -$763K 0.68% 61
2024
Q4
$51.7M Buy
519,589
+16,392
+3% +$1.69M 0.73% 54
2024
Q3
$57.1M Sell
503,197
-8,095
-2% -$962K 0.79% 50
2024
Q2
$63.3M Sell
511,292
-15,953
-3% -$2.05M 0.9% 45
2024
Q1
$69.6M Buy
527,245
+23,765
+5% +$2.93M 0.98% 38
2023
Q4
$54.9M Buy
503,480
+1,142
+0.2% +$119K 0.85% 54
2023
Q3
$51.7M Sell
502,338
-5,805
-1% -$626K 0.87% 47
2023
Q2
$58.6M Sell
508,143
-15,405
-3% -$1.75M 0.95% 45
2023
Q1
$55.7M Sell
523,548
-14,584
-3% -$1.57M 0.93% 48
2022
Q4
$59.7M Sell
538,132
-31,234
-5% -$3.19M 1% 46
2022
Q3
$49M Sell
569,366
-3,902
-0.7% -$348K 0.91% 43
2022
Q2
$52.3M Sell
573,268
-6,227
-1% -$552K 0.89% 44
2022
Q1
$47.5M Sell
579,495
-3,786
-0.6% -$298K 0.67% 61
2021
Q4
$44.7M Buy
583,281
+15,249
+3% +$1.21M 0.59% 71
2021
Q3
$42.7M Buy
568,032
+45,775
+9% +$3.48M 0.61% 68
2021
Q2
$40.6M Buy
522,257
+13,727
+3% +$1.02M 0.57% 73
2021
Q1
$37.4M Buy
508,530
+22,745
+5% +$1.68M 0.58% 70
2020
Q4
$37.9M Sell
485,785
-1,123
-0.2% -$85.9K 0.64% 61
2020
Q3
$38.5M Buy
486,908
+13,683
+3% +$1.07M 0.76% 51
2020
Q2
$34.9M Buy
473,225
+2,125
+0.5% +$160K 0.75% 51
2020
Q1
$34.6M Sell
471,100
-28,685
-6% -$2.25M 0.91% 43
2019
Q4
$43.4M Buy
499,785
+5,933
+1% +$487K 0.81% 51
2019
Q3
$39.7M Sell
493,852
-4,532
-0.9% -$363K 0.79% 51
2019
Q2
$39.9M Sell
498,384
-17,983
-3% -$1.38M 0.78% 54
2019
Q1
$41M Sell
516,367
-15,642
-3% -$1.17M 0.85% 53
2018
Q4
$38.8M Sell
532,009
-13,294
-2% -$938K 0.92% 48
2018
Q3
$36.9M Buy
545,303
+323
+0.1% +$20.6K 0.73% 61
2018
Q2
$31.6M Buy
544,980
+3,582
+0.7% +$202K 0.67% 64
2018
Q1
$28.1M Buy
541,398
+63,589
+13% +$3.43M 0.61% 70
2017
Q4
$25.7M Buy
477,809
+22,837
+5% +$1.27M 0.54% 68
2017
Q3
$27.8M Sell
454,972
-7,701
-2% -$467K 0.64% 68
2017
Q2
$28.3M Sell
462,673
-7,810
-2% -$475K 0.67% 64
2017
Q1
$28.5M Sell
470,483
-9,112
-2% -$553K 0.71% 63
2016
Q4
$26.9M Sell
479,595
-17,681
-4% -$1.03M 0.69% 58
2016
Q3
$29.6M Sell
497,276
-12,435
-2% -$727K 0.79% 55
2016
Q2
$28M Sell
509,711
-6,152
-1% -$327K 0.8% 53
2016
Q1
$26M Buy
+515,863
New +$25.3M 0.71% 55

Other funds holding MRK

Douglas Lane & Associates's MRK Position: Q2 2026 in Review

Douglas Lane & Associates reduced its Merck (MRK) stake by 1.7% in Q2 2026, selling an estimated $1.14M and leaving 552,155 shares worth $71M. The position accounts for 0.96% of the portfolio, ranked #33.

Douglas Lane & Associates first reported a position in MRK in Q1 2016 and has held it in 42 quarters since. 1,477 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Douglas Lane & Associates held 552,155 shares of Merck worth $71M as of Q2 2026.
  • Douglas Lane & Associates sold 9,737 Merck shares in Q2 2026, an estimated $1.14M.
  • Merck made up 0.96% of Douglas Lane & Associates's portfolio in Q2 2026, its #33 holding.
  • Douglas Lane & Associates first reported a position in Merck in Q1 2016 and has held it in 42 quarters since.
  • 1,477 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.